Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	4.78B
Revenue (ttm)	1.24B
Net Income (ttm)	410.38M
Shares Out	n/a
EPS (ttm)	0.53
PE Ratio	11.65
Forward PE	n/a
Dividend	0.23 (8.21%)
Ex-Dividend Date	Jun 25, 2025

Volume	128,300
Average Volume	210,555
Open	2.750
Previous Close	2.760
Day's Range	2.730 - 2.780
52-Week Range	1.990 - 2.790
Beta	n/a
RSI	71.26
Earnings Date	Aug 15, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY